Ingelheim, Germany, and St. Joseph, Mo. -- Boehringer Ingelheim (BI) completed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business, the company reports.
Ingelheim, Germany, and St. Joseph, Mo.
-- Boehringer Ingelheim (BI) completed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business, the company reports.
The acquisition includes products in the United States, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa. The deal significantly increases the size of BI’s companion-animal and cattle portfolios and strengthens its position as a vaccine supplier, the company says.
Terms of the deal were not disclosed. Products being acquired in Europe are still subject to approval by European antitrust authorities, BI reports.
“Boehringer Ingelheim and Fort Dodge share a strong commitment to innovation, and this will continue to be the imperative basis of all our activities as we move forward,” Hubertus von Baumbach, member of the Board of Managing Directors of BI, responsible for finance and animal health, said in a prepared statement. “With the closing of this deal, our attention now turns to ensuring a seamless integration of the highly committed teams of people as well as the transition of the product portfolio."
As part of the deal, BI will acquire the Duramune® line of vaccines for dogs, the Fel-O-Vax® line of vaccines for cats and the Rabvac® line of rabies vaccines manufactured and sold in the United States, Canada and Australia. In addition, a portfolio of pet and equine pharmaceutical products currently sold in the United States is included in the deal. The company will acquire cattle vaccines in the United States and Canada, including the Triangle®, Pyramid® and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®. Several Canadian swine vaccines are included in the acquisition, as are some cattle vaccines sold in Europe and South Africa.
“The products included in this acquisition complement our already strong product lines and help to broaden our innovation base across more species and boost our global pipeline,” says Prof. Andreas Barner, chairman of the Board of Managing Directors of BI. “We look forward to applying our innovative culture to the products included in this acquisition as well as to the research and discovery of new products that will continue to bring value to our customers and our business.”